News
Public · Published
UBS maintains Alnylam Pharmaceuticals at Buy, lowers price target to $329 from $354
UBS kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $329 from $354, a 7.1% reduction. UBS said the new target represented 99.4% upside from the stock's October 30 closing price of $165.
Published:
Updated:
What happened
UBS kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $329 from $354, a 7.1% reduction. UBS said the new target represented 99.4% upside from the stock’s October 30 closing price of $165.
Confirmed
Global impact / market context
The lower target signals that UBS reduced its estimate of where Alnylam shares could trade, even while retaining a Buy rating. That change may influence investor expectations and positioning, but the article gives no reason for the cut or evidence of a company-level change.
Analyst inference
Recent analyst views were spread across a wide range: the five reported targets span $199 to $354, with ratings including Buy, Equal-Weight and Market Perform. This disagreement suggests investors face differing expectations; it does not establish which forecast will prove accurate.
Confirmed
What to watch
- Watch for any later UBS update explaining the lower target or changing its Buy rating; the article provides no rationale for the revision. Analyst inference
- Compare future analyst targets and ratings with the reported $199–$354 range to see whether the spread narrows or widens. Analyst inference
- Track whether Alnylam’s subsequent company disclosures provide information that could clarify the differing analyst expectations; no such developments are reported here. Analyst inference
Evidence
- Original source link unavailable